Anti-VEGF Monoclonal Antibody(Bevacizumab)

產(chǎn)品型號：S0B0557

更新時間：2025-06-30

廠商性質(zhì)：生產(chǎn)廠家

訪問量：41

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

水痘-帶狀皰疹病毒(VZV)：引爆醫(yī)藥界百億爭奪戰(zhàn)的黑馬

視黃醇結(jié)合蛋白4（RBP4）抗體：發(fā)掘其在疾病風(fēng)險中的診斷潛力

抗體試劑盒“避坑指南”：如何通過驗證數(shù)據(jù)、交叉反應(yīng)率、批次穩(wěn)定性選對產(chǎn)品？

FLAG標(biāo)簽蛋白的結(jié)構(gòu)與功能解析

產(chǎn)品介紹

Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor. For cancer, it is given by slow injection into a vein （intravenous） and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye （intravitreal）.

上一個：S0B0558Anti-EGFR Monoclonal Antibody(Cetuximab)